Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FACTS I: OPC-6535 in Active Ulcerative Colitis
NCT00064441Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- May 2003
- Primary completion
- May 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of tetomilast in ulcerative colitis (UC), sponsored by Otsuka Pharmaceutical Development & Commercialization. Started May 2003; status: completed.
02
Drugs
tetomilast
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT00064441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00064441.